The global DNA microarray market size was USD 1.84 Bn in 2022 and is likely to reach USD 3.80 Bn by 2031, expanding at a CAGR of 8.4% during 2023–2031. The market growth is attributed to the increasing use of DNA microarrays in gene expression.
Microarray is used to detect the expression of thousands of genes at the same time, which is likely to boost the demand for DNA microarray in gene expression. DNA microarrays are microscope slidesin which thousands of tiny spots are defined, and each spot is containing different DNA sequences or genes. These DNA sequences are complementary to specific target genes or regions of interest.
Researchers gain insights into gene expression profiles that identify differentially expressed genes between samples and study interactions between genes and proteins. These factors are likely to surge in research activities. DNA microarrays have been instrumental in numerous areas of research, pharmacogenomics, transcriptomics, including genomics, and personalized medicine. For instance,
-
In January 2023, the National Institutes of Health (NIH) announced a microarray system to detect the UDP-glucuronosyl transferase gene polymorphismsUGT1A1*6 and UGT1A1*28 for use in clinical laboratories in patients eligible for irinotecan hydrochloride treatment.The surface treatment technology used in the system enables high-density and strong DNA fixation, which allows the construction of a measurement system suitable for clinical applications.
The market report finds that the COVID-19 pandemic has positively impacted the market. Increasing penetration of DNA microarray by different end-users such as biopharmaceutical & pharmaceutical companies is expected to drive the market. Several research institutes are focusing to develop new products to detect COVID-19. For instance,
-
In April 2021, the National Institutes of Health (NIH), announced to introduced Covid Array, a microarray-based assay, to detect SARS-CoV-2 markers N1 and N2 in the nasopharyngeal swabs. This microarray can detect the genotypes of six mutated bases related to COVID-19.
DNA Microarray Market Dynamics
Major Drivers
Increasing research & development (R&D) activities for technological advancements are likely to fuel the DNA microarray market. Several end-users such as research institutes and biotechnology & pharmaceutical companies are focusing on developing new technologies for DNA microarrays.
-
According to the National Institutes of Health, DNA microarrays are developed to identify the bacteria in lung diseases, but they can detect no more than two target genes. One conserved gene and one species-specific gene, including the rDNA gene and various phylogenetically conserved genes.
The rising adoption of genetic testing is expected to boost the DNA microarray market. Genetic testing can detect small missing or extra pieces of chromosomes and helps to identify the underlying cause of children’s medical conditions.
-
On April 15, 2020, Axovant Gene Therapies Ltd., a clinical-stage company announced its collaboration with Invitae Corporation to increase access to genetic testing and accelerate diagnoses of GM1 and GM2 gangliosidosis, also known as Tay-Sachs/Sandhoff disease.This partnership is to reduce the barriers to genetic barriers through sponsored testing for lysosomal storage diseases. The initiative supports the identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed and undiagnosed.
Existing Restraints
The high cost of microarrays is expected to hamper the DNA microarray market. Depending on the platform, an experiment can cost hundreds if not thousands of dollars, and there is currently no agreement on how many replicates should be done, but fortunately, the number appears to be low.
Emerging Opportunities
The high demand for R&D activities in cancer and the increasing prevalence of cancer is expected to create lucrative opportunities for the market players. A microarray is used to identify small genetic changes such as single nucleotide polymorphisms (SNP). DNA microarray technology has become a major tool for the investigation of gene expression in all aspects of human disease and biomedical research.
Increasing strategic initiatives by key players to strengthen personalized medicine and genotyping capabilities is expected to create lucrative opportunities for the market players. For instance, Cancer treatment has proven that microarrays are used to develop a new taxonomy of cancer, including genesis, prognosis, progression, and response to the therapy based on gene expression.
-
On May 23, 2022, Thermo Fisher Scientific, a world leader in serving science partnered with the Qatar Genome program to develop personalized medicine across Arab populations globally. Thermo fisher scientific will develop an Axiom custom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab Countries. The array aims to help drive scientific research and insights into conditions including cardiovascular, diabetes, metabolic diseases, autism, genetic disorders, and cancer.
Scope of DNA Microarray Market Report
The market report includes an assessment of the market trends, marketsegments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
DNA Microarray Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Oligonucleotide DNA Microarrays and Complementary DNA Microarrays), Application (Gene Expression, Genotyping, Mutation Analysis, and Others), and End-User (Hospitals, Diagnostic Centers, Academic &Research Institutes, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, market trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Thermo Fisher Scientific Inc.; QIAGEN; PerkinElmer Inc.; Microarrays Inc.; Merck KGaA; Illumina, Inc.; F. Hoffmann-La Roche Ltd; BIOMÉRIEUX; Ancestry; SCIENION; Applied Micro Arrays; and Agilent Technologies, Inc.
|
DNA Microarray Market Segment Insights
Type Segment Analysis
Based on type, the DNA microarray market is divided into oligo nucleotide DNA microarrays and complementary DNA micro arrays. The oligo nucleotide DNA microarrays segment is expected to expand at a significant pace during the projection period, as its higher capability to monitor the expression of every gene in the genome.
In oligonucleotide DNA microarrays, the probes are short sequences that are designed to match parts of the predicted open reading frames. Although oligonucleotide probes are often used in spotted microarrays and most often refer to a specific technique of manufacturing.DNA microarrays are powerful tools for identifying gene expression and genes.
The complementary DNA microarrays (cDNA) segment is anticipated to hold a key share of the market in the coming years, as its powerful tool for studying gene expression in several organisms. Increasing the use of complementary DNA microarrays in a wide range of applications such as polymorphism screening, large-scale gene discovery, and mapping of genomic DNA clones is expected to boost the segment in the market.
Application Segment Analysis
On the basis of application, the market is segregated into gene expression, genotyping, mutation analysis, and others. The gene expression segment is projected to register a considerable CAGR during the forecast period, due to the increasing adoption of gene expression in several applications such as drug discovery, clinical diagnostics, microbiology, and others.
It shows the simultaneous changes in the expression of different genes to a particular treatment and condition.The genotyping segment is anticipated to account for a major market share in the coming years, due to the increasing research & development for precision medicine and strategic initiatives taken by the market players.
-
In February 2021, 23 and Me merged with Virgin Group’s VG Acquisition Corp. to develop personalized healthcare and therapeutic development through human genetics. This acquisition provides the fund additional investment in key growth initiatives across 23andMe’s consumer health and therapeutics business.
End User Segment Analysis
Based on end-user, the DNA microarray market is segmented into hospitals, diagnostic centers, academic & research institutes, and others. The academic & research institutes segment is expected to register a robust growth rate during the forecast period, owing rising implementation of microarrays in drug discovery applications.
The microarray is an advantage to the researchers, as it provides a platform for the testing of a large set of genetic samples. The diagnostic centers segment is projected to hold a large market share in the coming years. Diagnostic centers are expected to rise the demand for numerous products offered by several companies that are used to diagnose infectious diseases, autoimmune diseases, cancers, and others.
Regional Analysis
In terms of region, the global DNA microarray market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the increasing technological advanced DNA microarray products and the presence of well-established research infrastructure.
Increasing adoption of DNA microarray technologies from academic laboratories to biopharmaceutical companies is expected to fuel the market in the region. The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, increasing awareness about genetic testing, and high prevalence of target disease. Increasing investments by key players to develop novel DNA microarray products are expected to drive the market in the region.
Segments
The global DNA microarray market has been segmented on the basis of
Type
- Oligonucleotide DNA Microarrays
- Complementary DNA Microarrays
Application
- Gene Expression, Genotyping
- Mutation Analysis
- Others
End-User
- Hospitals
- Diagnostic Centers
- Academic &Research Institutes
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global DNA microarray market are Thermo Fisher Scientific Inc.; QIAGEN; PerkinElmer Inc.; Microarrays Inc.; Merck KGaA; Illumina, Inc.; F. Hoffmann-La Roche Ltd; BIOMÉRIEUX; Ancestry; SCIENION; Applied Micro Arrays; and Agilent Technologies, Inc.
These key players adopt various strategies including mergers, acquisitions, collaboration, partnerships, product launches, and production expansion to expand their consumer base globally.
-
In August 2020, Ancestry launched Ancestry Health powdered by Next Generation Sequencing (NGS), signifying an era in consumer’s access to important information about health. It is designed to help people to understand their risks for developing certain inheritable health conditions.
-
In March 2020, Agilent Technologies introduced new three microarrays for prenatal and postnatal research. The new Agilent Genetic Sure Crypto microarrays include updated and clinically relevant from respected databases.
Request For Customization
Enquiry Before Buying
Speak With Analyst
